Head-To-Head Review: Veracyte (NASDAQ:VCYT) & Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Veracyte	20.37%	9.26%	8.61%

Volatility and Risk

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.

Earnings & Valuation

This table compares Lakefront Biotherapeutics American Depositary Shares and Veracyte”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.40	$363.05 million	($1.41)	-19.01
Veracyte	$517.15 million	6.35	$66.35 million	$1.41	28.99

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Veracyte. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Lakefront Biotherapeutics American Depositary Shares and Veracyte, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	7	1	1	2.33
Veracyte	1	2	5	3	2.91

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $30.67, suggesting a potential upside of 14.39%. Veracyte has a consensus price target of $55.78, suggesting a potential upside of 36.48%. Given Veracyte’s stronger consensus rating and higher possible upside, analysts plainly believe Veracyte is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Institutional and Insider Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Veracyte beats Lakefront Biotherapeutics American Depositary Shares on 11 of the 15 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.